NGFR and melanoma: HSP90, NGFR, AXL, and HDAC inhibitors have all been shown to variably suppress the de-differentiated melanoma phenotype, but the treatment of the de-differentiated PD1 PROG cells with HSP90 inhibitors (Ganetespib at 50 nM or 250 nM, 17-AAG at 300 nM), NGFR inhibitor (1 μM Tyrphostin AG-879), histone deacetylase inhibitor (25 nM panobinostat), or AXL inhibitor (1 μM R428) did not restore expression of differentiation markers, SOX10, MITF, and Melan-A (Supplementary Fig. S4).